---
title: "NervGen Pharma Reports Positive Results from Phase 1b/2a CONNECT Study in Chronic Spinal Cord Injury"
description: "NervGen Pharma Corp. announced positive results from its Phase 1b/2a CONNECT Study for chronic spinal cord injury. The company will present clinical data at the Unite2Fight Paralysis’ 20th Annual Scie"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/275600172.md"
published_at: "2026-02-11T12:00:41.000Z"
---

# NervGen Pharma Reports Positive Results from Phase 1b/2a CONNECT Study in Chronic Spinal Cord Injury

> NervGen Pharma Corp. announced positive results from its Phase 1b/2a CONNECT Study for chronic spinal cord injury. The company will present clinical data at the Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium on February 15-17, 2026, in Washington, DC. The data shows durable improvements in function, independence, and quality of life for individuals treated with NVG-291. This announcement is for informational purposes only and should not be considered financial or legal advice.

NervGen Pharma Corp., a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurologic conditions, announced it will present clinical data from the Phase 1b/2a CONNECT SCI Study at the Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium, scheduled for February 15-17, 2026, in Washington, DC. The presentation will discuss data demonstrating durable improvement in function, independence, and quality of life in individuals with chronic spinal cord injury treated with its lead therapeutic candidate, NVG-291. Results from the study will be presented at the upcoming symposium. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652624-en) on February 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [NGEN.US - NervGen Pharma](https://longbridge.com/en/quote/NGEN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NervGen Pharma ernennt Adam Rogers zum CEO | NervGen Pharma Corp. has appointed Adam Rogers, MD, as the new President and Chief Executive Officer, effective immediat | [Link](https://longbridge.com/en/news/275312873.md) |
| Natco Pharma Says API Unit In Chennai Receives Establishment Inspection Report From U.S. FDA | Natco Pharma Ltd :NATCO PHARMA - API UNIT IN CHENNAI RECEIVES ESTABLISHMENT INSPECTION REPORT FROM U.S. FDANATCO PHARMA  | [Link](https://longbridge.com/en/news/275846236.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.